Drawing for QIAGEN GENEREAD

USPTO serial 79136407

QIAGEN GENEREAD

Reviewed by CopyMark Law Group

Reg. 4824206Status 404
Filing date
Status date
Registration date
Oct 6, 2015
Examiner
RAPPAPORT, SETH
Law office
GENERIC WEB UPDATE

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with QIAGEN GENEREAD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Victoria Friedman

Victoria Friedman Dennemeyer & Associates, LLC2 North Riverside Plaza, Suite 1500Chicago, IL 60606UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, diagnostic preparations except for human or veterinary medical purposes, non-medical chemical reagents, enzymes and chemicals solutions in the nature of buffer solutions for scientific and/or medical research use for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; kits comprising chemicals for laboratory or research use for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular nucleic acids of biological or biochemical sample material, in particular comprising chemicals for reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencingSECTION 70 - CANCELLED—
005Diagnostic preparations for medical purposes; diagnostic preparations for veterinary purposes; diagnostic preparations for humans for medical purposes; preparations for medical and veterinary purposes, namely, diagnostic preparations, for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; chemical, biochemical and biotechnological preparations for medical and veterinary purposes, namely, diagnostic reagents, enzymes and diagnostic reagents in the nature of buffer solutions for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencing; kits containing preparations for medical and veterinary diagnostic purposes primarily consisting of diagnostic preparations for sample preparation, modification and manipulation of cells and for marking, separating, isolating, purifying, duplicating, sequencing and/or for the analysis of biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances, in particular reagents, enzymes and buffer solutions for nucleic acid purification, enrichment, amplification and sequencingSECTION 70 - CANCELLED—
009Computer software for use in scientific and medical research for assisting in analyzing and sequencing biomolecules, namely, nucleic acidsSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Feb 4, 2024DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Feb 4, 2024DETHDEATH OF INTERNATIONAL REGISTRATION—
Jul 6, 2022NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Jul 6, 2022C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Jul 5, 2022APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 20, 2021ES75TEAS SECTION 71 & 15 RECEIVED—
Oct 6, 2020REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 18, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 18, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 29, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 29, 2016FIMPFINAL DISPOSITION PROCESSED—
Jan 6, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 6, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 21, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 21, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 17, 2015GPNXNOTIFICATION PROCESSED BY IB—
Jul 1, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 1, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 1, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 16, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 16, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 16, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Jun 16, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 16, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 16, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 20, 2015OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 4, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 4, 2015OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Dec 29, 2014TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 18, 2014GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Nov 18, 2014GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 18, 2014CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 18, 2014ALIEASSIGNED TO LIE—
Aug 22, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 15, 2014GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
May 15, 2014GNSLLETTER OF SUSPENSION E-MAILED—
May 15, 2014CNSLSUSPENSION LETTER WRITTEN—
May 10, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 10, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 28, 2014ALIEASSIGNED TO LIE—
Apr 9, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 23, 2013RFNTREFUSAL PROCESSED BY IB—
Nov 1, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 30, 2013RFRRREFUSAL PROCESSED BY MPU—
Oct 30, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 29, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 25, 2013DOCKASSIGNED TO EXAMINER—
Oct 15, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 10, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 3, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance